Risk of anaphylaxis after vaccination of children and adolescents
- PMID: 14523172
- DOI: 10.1542/peds.112.4.815
Risk of anaphylaxis after vaccination of children and adolescents
Abstract
Objective: To quantify the risk of anaphylaxis after vaccination of children and adolescents.
Methods: The study population consisted of children and adolescents who were enrolled at 4 health maintenance organizations that participated in the Vaccine Safety Datalink Project. For the period 1991-1997, we identified potential cases by searching for occurrences of International Classification of Diseases, Ninth Revision (ICD-9) code 995.0 (anaphylactic shock), E948.0 through E948.9 (adverse reaction from bacterial vaccines), and E949.0 through E949.9 (adverse reaction from other vaccines and biological substances). At 1 study site, we also included a range of other allergy codes. We restricted to diagnoses on days 0 to 2 after vaccination (ICD-9 995.0) or day 0 (all other ICD-9 codes). We then reviewed the medical record to confirm the diagnosis.
Results: We identified 5 cases of potentially vaccine-associated anaphylaxis after administration of 7 644 049 vaccine doses, for a risk of 0.65 cases/million doses (95% confidence interval: 0.21-1.53). None of the episodes resulted in death. Vaccines that were administered before the anaphylactic episodes were generally given in combination and included measles-mumps-rubella, hepatitis B, diphtheria-tetanus, diphtheria-tetanus-pertussis, Haemophilus influenzae type b, and oral polio vaccine. One case of anaphylaxis followed measles-mumps-rubella vaccine alone. At the site at which we reviewed additional allergy codes, we identified 1 case after 653 990 vaccine doses, for a risk of 1.53 cases/million doses (95% confidence interval: 0.04-8.52).
Conclusions: Patients and health care providers can be reassured that vaccine-associated anaphylaxis is a rare event. Nevertheless, providers should be prepared to provide immediate medical treatment should it occur.
Similar articles
-
Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine.JAMA. 1994 May 25;271(20):1602-5. JAMA. 1994. PMID: 8182813
-
Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team.Pediatrics. 1997 Jun;99(6):765-73. doi: 10.1542/peds.99.6.765. Pediatrics. 1997. PMID: 9164767
-
Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.Pediatrics. 2002 Dec;110(6):e71. doi: 10.1542/peds.110.6.e71. Pediatrics. 2002. PMID: 12456938
-
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.BioDrugs. 2001;15(6):413-8. doi: 10.2165/00063030-200115060-00007. BioDrugs. 2001. PMID: 11520252 Review.
-
Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2009 Feb. SBU Yellow Report No. 191. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2009 Feb. SBU Yellow Report No. 191. PMID: 28876765 Free Books & Documents. Review.
Cited by
-
Oral and Extra-Oral Manifestations of Hypersensitivity Reactions in Orthodontics: A Comprehensive Review.J Funct Biomater. 2024 Jun 27;15(7):175. doi: 10.3390/jfb15070175. J Funct Biomater. 2024. PMID: 39057297 Free PMC article. Review.
-
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022.Can Commun Dis Rep. 2024 Jan 1;50(1-2):16-24. doi: 10.14745/ccdr.v50i12a02. eCollection 2024 Jan 1. Can Commun Dis Rep. 2024. PMID: 38655243 Free PMC article.
-
Anaphylactic deaths: A retrospective study of forensic autopsy cases from 2009 to 2019 in Shanghai, China.Heliyon. 2024 Mar 12;10(6):e28049. doi: 10.1016/j.heliyon.2024.e28049. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38515709 Free PMC article.
-
Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021.Pan Afr Med J. 2023 Jul 14;45(Suppl 2):6. doi: 10.11604/pamj.supp.2023.45.2.40228. eCollection 2023. Pan Afr Med J. 2023. PMID: 38370101 Free PMC article.
-
Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy).Front Immunol. 2023 Feb 27;14:1074246. doi: 10.3389/fimmu.2023.1074246. eCollection 2023. Front Immunol. 2023. PMID: 36923411 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical